FinnGen academic-industry genome research partnership

https://www.finngen.fi

FinnGen is one of the very first personalized medicine projects at this scale and the public-private collaborative nature of the project is exceptional compared to many ongoing studies. FinnGen brings together Finnish universities, hospitals and hospital districts, THL, Blood Service, biobanks and international pharmaceutical companies and hundreds of thousands of Finns. Because collaboration is the key to achieving breakthroughs in disease prevention, diagnosis, and treatment, we welcome everyone on this journey into our shared heritage. Industry partners include Abbvie, AstraZeneca, Biogen, Bristol-Myers Squibb, Genentech, a member of the Roche Group, GlaxoSmithKline (GSK), Jannsen (JnJ), Maze Therapeutics, MSD (the tradename of Merck & Co., Inc, Kenilworth, NJ USA), Pfizer and Sanofi. *

	Start	2020-02-25 existent
	Industry	genomics
	Industry 2	personalised medicine / precision medicine
	Person	Palotie, Aarno (Univ Helsinki 202002 Prof + Research Director of FIMM + Head of FinnGen)

	Region	Helsinki
	Country	Finland
	Street	8 Tukholmankatu c/o FIMM, University of Helsinki
	City	00290 Helsinki
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«: FinnGen. (2/25/20). "Press Release: FinnGen Welcomes Janssen and Maze Therapeutics".

		Record changed: 2024-02-12

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for FinnGen academic-industry genome research partnership

[1] FinnGen. (2/25/20). "Press Release: FinnGen Welcomes Janssen and Maze Therapeutics"....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]